Northwestern Mutual Wealth Management Co. decreased its holdings in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 42.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 895 shares of the company’s stock after selling 669 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Ionis Pharmaceuticals were worth $55,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also modified their holdings of IONS. Rockefeller Capital Management L.P. grew its stake in shares of Ionis Pharmaceuticals by 13,213.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 489,651 shares of the company’s stock worth $29,579,000 after acquiring an additional 485,973 shares during the last quarter. Baillie Gifford & Co. grew its stake in shares of Ionis Pharmaceuticals by 4.5% in the fourth quarter. Baillie Gifford & Co. now owns 8,790,025 shares of the company’s stock worth $531,006,000 after acquiring an additional 374,736 shares during the last quarter. Great Point Partners LLC acquired a new stake in shares of Ionis Pharmaceuticals in the third quarter worth $16,176,000. Scout Investments Inc. acquired a new stake in shares of Ionis Pharmaceuticals in the fourth quarter worth $15,635,000. Finally, Renaissance Technologies LLC grew its stake in shares of Ionis Pharmaceuticals by 12.4% in the fourth quarter. Renaissance Technologies LLC now owns 2,038,711 shares of the company’s stock worth $123,159,000 after acquiring an additional 225,700 shares during the last quarter. 86.60% of the stock is owned by institutional investors.
Shares of NASDAQ IONS traded up $2.09 during midday trading on Thursday, reaching $48.84. 937,182 shares of the company traded hands, compared to its average volume of 1,375,577. The firm has a market cap of $6.51 billion, a PE ratio of 23.59 and a beta of 2.04. The stock’s 50-day simple moving average is $53.59 and its 200-day simple moving average is $58.68. Ionis Pharmaceuticals Inc has a 12 month low of $39.32 and a 12 month high of $86.58. The company has a debt-to-equity ratio of 0.47, a quick ratio of 9.90 and a current ratio of 9.97.
Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $1.28 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.91 by $0.37. The company had revenue of $494.00 million during the quarter, compared to analysts’ expectations of $407.05 million. Ionis Pharmaceuticals had a return on equity of 22.23% and a net margin of 26.09%. The business’s revenue was up 157.3% on a year-over-year basis. During the same period last year, the business earned $2.21 earnings per share. On average, equities research analysts expect that Ionis Pharmaceuticals Inc will post -0.06 EPS for the current year.
In related news, SVP Patrick R. O’neil sold 3,882 shares of Ionis Pharmaceuticals stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $59.60, for a total value of $231,367.20. Following the completion of the transaction, the senior vice president now directly owns 20,720 shares of the company’s stock, valued at $1,234,912. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Stanley T. Crooke sold 15,000 shares of Ionis Pharmaceuticals stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $45.17, for a total value of $677,550.00. Following the completion of the transaction, the chairman now directly owns 61,545 shares of the company’s stock, valued at $2,779,987.65. The disclosure for this sale can be found here. Over the last three months, insiders have sold 19,055 shares of company stock valued at $919,340. Company insiders own 2.40% of the company’s stock.
Several equities research analysts have recently issued reports on IONS shares. William Blair restated a “hold” rating on shares of Ionis Pharmaceuticals in a research note on Friday, January 24th. Needham & Company LLC reiterated a “buy” rating and set a $87.00 price target on shares of Ionis Pharmaceuticals in a research note on Monday, December 23rd. BMO Capital Markets reiterated a “buy” rating and set a $86.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday, January 30th. Citigroup assumed coverage on shares of Ionis Pharmaceuticals in a research note on Thursday, March 5th. They set a “buy” rating and a $73.00 price target on the stock. Finally, TheStreet upgraded shares of Ionis Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Wednesday, February 26th. One analyst has rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $72.64.
Ionis Pharmaceuticals Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Further Reading: Why is momentum important to successful trading?
Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.